Pemazyre Dosage & Drug Information

Concise Prescribing Info

Contents

Pemigatinib

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Indications/Uses

Locally advanced or metastatic cholangiocarcinoma w/ fibroblast growth factor receptor 2 fusion or rearrangement that has progressed after at least 1 prior line of systemic therapy in adults.

Dosage/Direction for Use

Adult 13.5 mg once daily for 14 days followed by 7 days off therapy. May be reduced for toxicity management to 9 mg once daily for 14 days followed by 7 days off therapy; may be further decreased to 4.5 mg once daily for 14 days followed by 7 days off therapy. Concomitant use w/ strong or moderate CYP3A4 inhibitors Reduce to 9 mg once daily if taking 13.5 mg once daily; reduce to 4.5 mg once daily if taking 9 mg once daily. Severe renal & hepatic impairment Reduce to 9 mg once daily if taking 13.5 mg once daily; reduce to 4.5 mg once daily if taking 9 mg once daily.

Administration

May be taken with or without food: Do not crush/chew/split/dissolve. Avoid grapefruit juice.

Contraindications

Hypersensitivity. Concomitant use w/ St. John's wort.

MIMS Class

Cancer Immunotherapy

ATC Classification

L01EN02 - pemigatinib ; Belongs to the class of Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Pemazyre tab 4.5 mg

Packing/Price

1's

Form

Pemazyre tab 9 mg

Packing/Price

1's

Form

Pemazyre tab 13.5 mg

Packing/Price

1's

Pemazyre

Manufacturer:

Lonza Tampa LLC